These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 9573546

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Atrial natriuretic peptide gene delivery attenuates gentamycin-induced nephrotoxicity in rats.
    Murakami H, Yayama K, Chao J, Chao L.
    Nephrol Dial Transplant; 1999 Jun; 14(6):1376-84. PubMed ID: 10382996
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.
    Wolf WC, Yoshida H, Agata J, Chao L, Chao J.
    Kidney Int; 2000 Aug; 58(2):730-9. PubMed ID: 10916096
    [Abstract] [Full Text] [Related]

  • 6. Gene therapy in hypertension: adenovirus-mediated kallikrein gene delivery in hypertensive rats.
    Jin L, Zhang JJ, Chao L, Chao J.
    Hum Gene Ther; 1997 Oct 10; 8(15):1753-61. PubMed ID: 9358025
    [Abstract] [Full Text] [Related]

  • 7. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats.
    Yayama K, Wang C, Chao L, Chao J.
    Hypertension; 1998 May 10; 31(5):1104-10. PubMed ID: 9576121
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats.
    Dobrzynski E, Yoshida H, Chao J, Chao L.
    Immunopharmacology; 1999 Oct 15; 44(1-2):57-65. PubMed ID: 10604525
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Experimental kallikrein gene therapy in hypertension, cardiovascular and renal diseases.
    Chao J, Chao L.
    Pharmacol Res; 1997 Jun 15; 35(6):517-22. PubMed ID: 9356201
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Renal phenotype of low kallikrein rats.
    Madeddu P, Vio CP, Straino S, Salis MB, Milia AF, Emanueli C.
    Kidney Int; 2001 Jun 15; 59(6):2233-42. PubMed ID: 11380826
    [Abstract] [Full Text] [Related]

  • 15. Adenovirus-mediated kallikrein gene delivery reduces aortic thickening and stroke-induced death rate in Dahl salt-sensitive rats.
    Zhang JJ, Chao L, Chao J.
    Stroke; 1999 Sep 15; 30(9):1925-31; discussion 1931-2. PubMed ID: 10471446
    [Abstract] [Full Text] [Related]

  • 16. Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury.
    Bledsoe G, Shen B, Yao YY, Hagiwara M, Mizell B, Teuton M, Grass D, Chao L, Chao J.
    Toxicol Sci; 2008 Apr 15; 102(2):433-43. PubMed ID: 18227104
    [Abstract] [Full Text] [Related]

  • 17. Kallikrein gene therapy in newborn and adult hypertensive rats.
    Chao J, Yang Z, Jin L, Lin KF, Chao L.
    Can J Physiol Pharmacol; 1997 Jun 15; 75(6):750-6. PubMed ID: 9276159
    [Abstract] [Full Text] [Related]

  • 18. Adenovirus-mediated human tissue kallikrein gene delivery inhibits neointima formation induced by interruption of blood flow in mice.
    Emanueli C, Salis MB, Chao J, Chao L, Agata J, Lin KF, Munaò A, Straino S, Minasi A, Capogrossi MC, Madeddu P.
    Arterioscler Thromb Vasc Biol; 2000 Jun 15; 20(6):1459-66. PubMed ID: 10845858
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.